PURPOSE: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. EXPERIMENTAL DESIGN: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. RESULTS: In total, 18,880 unique peptides were identified (PeptideProphet peptide error rate ≤1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. CONCLUSIONS AND CLINICAL RELEVANCE: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for multiple reaction monitoring-MS. The availability of these datasets will contribute positively to clinical proteomics.
PURPOSE: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates humanbreast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. EXPERIMENTAL DESIGN: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. RESULTS: In total, 18,880 unique peptides were identified (PeptideProphet peptide error rate ≤1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. CONCLUSIONS AND CLINICAL RELEVANCE: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for multiple reaction monitoring-MS. The availability of these datasets will contribute positively to clinical proteomics.
Authors: Vladislav A Petyuk; Wei-Jun Qian; Charlotte Hinault; Marina A Gritsenko; Mudita Singhal; Matthew E Monroe; David G Camp; Rohit N Kulkarni; Richard D Smith Journal: J Proteome Res Date: 2008-06-21 Impact factor: 4.466
Authors: Harald Mischak; Rolf Apweiler; Rosamonde E Banks; Mark Conaway; Joshua Coon; Anna Dominiczak; Jochen H H Ehrich; Danilo Fliser; Mark Girolami; Henning Hermjakob; Denis Hochstrasser; Joachim Jankowski; Bruce A Julian; Walter Kolch; Ziad A Massy; Christian Neusuess; Jan Novak; Karlheinz Peter; Kasper Rossing; Joost Schanstra; O John Semmes; Dan Theodorescu; Visith Thongboonkerd; Eva M Weissinger; Jennifer E Van Eyk; Tadashi Yamamoto Journal: Proteomics Clin Appl Date: 2007-01-22 Impact factor: 3.494
Authors: Hasmik Keshishian; Terri Addona; Michael Burgess; D R Mani; Xu Shi; Eric Kuhn; Marc S Sabatine; Robert E Gerszten; Steven A Carr Journal: Mol Cell Proteomics Date: 2009-07-13 Impact factor: 5.911
Authors: Sharon J Pitteri; Karen S Kelly-Spratt; Kay E Gurley; Jacob Kennedy; Tina Busald Buson; Alice Chin; Hong Wang; Qing Zhang; Chee-Hong Wong; Lewis A Chodosh; Peter S Nelson; Samir M Hanash; Christopher J Kemp Journal: Cancer Res Date: 2011-06-08 Impact factor: 12.701
Authors: Limin Wang; Zhihao Zha; Wenchao Qu; Hongwen Qiao; Brian P Lieberman; Karl Plössl; Hank F Kung Journal: Nucl Med Biol Date: 2012-04-26 Impact factor: 2.408
Authors: Mitchell E Menezes; Swadesh K Das; Luni Emdad; Jolene J Windle; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Adv Cancer Res Date: 2014 Impact factor: 6.242
Authors: Mi-Youn K Brusniak; Caroline S Chu; Ulrike Kusebauch; Mark J Sartain; Julian D Watts; Robert L Moritz Journal: Proteomics Date: 2012-04 Impact factor: 3.984
Authors: Jeffrey R Whiteaker; Chenwei Lin; Jacob Kennedy; Liming Hou; Mary Trute; Izabela Sokal; Ping Yan; Regine M Schoenherr; Lei Zhao; Uliana J Voytovich; Karen S Kelly-Spratt; Alexei Krasnoselsky; Philip R Gafken; Jason M Hogan; Lisa A Jones; Pei Wang; Lynn Amon; Lewis A Chodosh; Peter S Nelson; Martin W McIntosh; Christopher J Kemp; Amanda G Paulovich Journal: Nat Biotechnol Date: 2011-06-19 Impact factor: 54.908
Authors: Marta Dueñas; Mirentxu Santos; Juan F Aranda; Concha Bielza; Ana B Martínez-Cruz; Corina Lorz; Miquel Taron; Eva M Ciruelos; José L Rodríguez-Peralto; Miguel Martín; Pedro Larrañaga; Jubrail Dahabreh; George P Stathopoulos; Rafael Rosell; Jesús M Paramio; Ramón García-Escudero Journal: PLoS One Date: 2012-08-07 Impact factor: 3.240